Which of the following is granted orphan drug status for the treatment of Dravet’s syndrome?
## **Core Concept**
Dravet's syndrome is a severe form of epilepsy that begins in infancy. It is characterized by prolonged seizures and developmental delays. Orphan drug status is granted to drugs that treat rare diseases, and such drugs often receive special incentives for their development.
## **Why the Correct Answer is Right**
Cannabidiol (CBD), specifically in the form of Epidiolex, has been granted orphan drug status for the treatment of Dravet's syndrome. CBD is a non-psychoactive compound found in the cannabis plant. It has shown efficacy in reducing the frequency of seizures in patients with Dravet's syndrome by interacting with various receptors in the brain, including the CB1 and CB2 cannabinoid receptors, as well as other non-cannabinoid receptors.
## **Why Each Wrong Option is Incorrect**
- **Option A:** While certain medications are used to treat epilepsy, there's no direct association mentioned here with Dravet's syndrome and orphan drug status specifically for this condition.
- **Option B:** Similarly, another antiepileptic drug, but not specifically granted orphan drug status for Dravet's syndrome.
- **Option D:** This option does not directly relate to the treatment of Dravet's syndrome with orphan drug status.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that cannabidiol (CBD), in the form of Epidiolex, is specifically approved for the treatment of Dravet syndrome and Lennox-Gastaut syndrome, two severe forms of epilepsy. This highlights the evolving role of cannabinoids in the management of neurological disorders.
## **Correct Answer:** .